Company profile
Prelude Therapeutics Inc
NASDAQ:PRLDBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Venetoclax | phase1 | — | 69 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (12)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07469891 | phase1 | recruiting | 2026-04-29 | 2028-04-01 | Prelude Therapeutics | A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms |
| NCT04837677 | phase1 | completed | 2021-08-11 | 2023-02-06 | Prelude Therapeutics | A Study of PRT1419 in Patients With Advanced Solid Tumors |
| NCT04543305 | phase1 | completed | 2020-09-28 | 2022-03-21 | Prelude Therapeutics | A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies |
| NCT05665530 | phase1 | completed | 2023-09-12 | 2025-06-12 | Prelude Therapeutics | A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies |
| NCT05159518 | phase1 | completed | 2022-02-14 | 2023-12-06 | Prelude Therapeutics | A Study of PRT2527 in Participants With Advanced Solid Tumors |
FDA applications (0)
No records yet.